Search clinical trials for: Rimonabant

Total 46 results

National Institute on Drug Abuse (NIDA)

Completed

Antagonist-Elicited Cannabis Withdrawal

Cannabis | Dependence

United States
Sanofi

Completed

Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation (STRATUS-EU)

Smoking Cessation

France, Spain, Sweden, Switzerland, Belgium, Denmark, United Kingdom
Sanofi

Completed

Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation (STRATUS-META)

Smoking Cessation

United States
Sanofi

Completed

Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch (CIRRUS)

Smoking Cessation

United States
Sanofi

Terminated

European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia (ETERNAL)

Obesity | Dyslipidemias

Germany, Netherlands, Turkey, Slovakia, United Kingdom, Finland, Hungary, Ireland, Italy, Norway, Greece, Sweden, Czech Republic, Portugal, Switzerland
Sanofi

Completed

Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients (SERENADE)

Type 2 Diabetes Mellitus

United States, Poland, Germany, Netherlands, Argentina, Hungary, Chile
Sanofi

Completed

Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation (STRATUS-WW)

Maintenance of Smoking Cessation

United States, Canada, Australia
Sanofi

Completed

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

Coronary Atherosclerosis

Canada, United States, Italy, Spain, Poland, Netherlands, Belgium, France, Australia
Sanofi

Terminated

Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)

Obesity

Japan
Weill Medical College of Cornell University
National Institutes of Health (NIH); PWSAUSA

Terminated

Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome (PWS)

Prader-willi Syndrome

United States
Sanofi

Terminated

Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients (MODERATO)

Obesity | Weight Loss

Romania, Netherlands, Croatia, Finland, Hungary
Sanofi

Completed

Obese Patients With or Without Comorbidities (RIO-North America)

Obesity | Weight Loss

United States, Canada
Sanofi

Completed

An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients (ADAGIO-lipids)

Obesity | Dyslipidemia

United States, Canada, Brazil, Australia, Italy, Sweden, Malaysia, Singapore, Taiwan, Mexico, Denmark, Korea, Republic of, Hong Kong, South Africa
Sanofi

Completed

Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

Type 2 Diabetes Mellitus

France, Russian Federation, United States, Argentina, Canada, Germany, South Africa, Italy, Netherlands, United Kingdom, Australia, Chile
Sanofi

Completed

Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)

Obesity

France, United States, Belgium, Germany, Netherlands, Sweden, Finland
Sanofi

Completed

Obese Patients With Untreated Dyslipidemias (RIO-Lipids)

Obesity | Dyslipidemia

United States, Canada, Australia, Italy, Spain, Sweden, Switzerland, Finland
Sanofi

Completed

Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients

Obesity | Eating Disorders

United States, France, Netherlands, Portugal, Sweden, Switzerland, Finland
Sanofi

Completed

Japanese Dose-Response Study of Rimonabant in Obese Patients

Obesity

Japan
Sanofi

Terminated

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes (CRESCENDO)

Cardiovascular Disease

United States, France, Brazil, Poland, Romania, Russian Federation, Germany, Italy, Netherlands, Portugal, Sweden, Switzerland, Turkey, India, Malaysia, Philippines, Singapore, Taiwan, Belgium, Czech Republic, Mexico, Tunisia, United... and more
Sanofi

Terminated

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes

Fatty Liver

United States, France, Brazil, Poland, Romania, Germany, Portugal, Spain, Switzerland, Malaysia, Philippines, Taiwan, Belgium, Mexico, Argentina, Croatia, Hungary, Italy, Colombia, Chile, United Kingdom, Puerto Rico, Australia, China
Sanofi

Terminated

An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

Fatty Liver

United States, France, Brazil, Poland, Romania, Germany, Portugal, Spain, Switzerland, Malaysia, Philippines, Taiwan, Belgium, Mexico, Argentina, Croatia, Hungary, Italy, Colombia, Chile, United Kingdom, Puerto Rico, Australia, China
Sanofi

Completed

Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients (REBA)

Obesity

United Kingdom
Sanofi

Completed

Obese Patients With Type 2 Diabetes (RIO-Diabetes)

Obesity | Diabetes Mellitus, Non-Insulin-Dependent | Obesity in Diabetes

United States, France, Canada, Poland, Germany, Netherlands, Belgium, Czech Republic, Argentina, Finland, United Kingdom
Sanofi

Completed

Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)

Obesity

China, Korea, Republic of, Taiwan
The Scripps Research Institute
National Institute on Drug Abuse (NIDA)

Completed

Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults (SCCAN)

Cannabis Dependence | Cannabis Withdrawal

United States
Sanofi

Terminated

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise (SOLO)

Obesity | Diabetes Mellitus Type 2

Japan
Sanofi

Completed

VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt (VICTORIA)

Metabolic Syndrome

United States, France, Canada, Spain, United Kingdom, Finland, Italy, Denmark, Sweden
University of Surrey
European Foundation for the Study of Diabetes; Royal Surrey County Hospital...

Terminated

The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition

Obesity

United Kingdom
Sanofi

Terminated

Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant (AUDITOR)

Arteriosclerosis | Obesity | Carotid Artery Plaque | Metabolic Syndrome X

United States, France, Canada, Netherlands, Spain, United Kingdom
Sanofi

Terminated

Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes (RAPSODI)

Prediabetic State

United States
National Institute on Alcohol Abuse and Alcoholism...
Sanofi-Synthelabo

Completed

Rimonabant to Reduce Alcohol Consumption

Alcohol Drinking | Healthy

United States
Sanofi

Terminated

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes (TOCCATA)

Diabetes Mellitus, Type 2

United States, Poland, Romania, Russian Federation, Ukraine, Malaysia, Philippines, Taiwan, Mexico, Lithuania, Slovakia, Indonesia, Thailand
Sanofi

Terminated

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug (SYMPHONY)

Obesity | Diabetes Mellitus Type 2

Japan
University Hospital, Clermont-Ferrand

Completed

Antagonistic Interaction CB1-paracetamol

Pain

France
Aristotle University Of Thessaloniki

Completed

Diagnosis and Therapy of Vulnerable Atherosclerotic Plaque

Stroke | Metabolic Syndrome | Type 2 Diabetes | Carotid Atherosclerosis

Greece
Sanofi

Completed

Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)

Smoking Cessation

United States
Sanofi

Terminated

High Density Lipoprotein Turnover

Obesity

France, United Kingdom, Finland, Australia
Sanofi

Terminated

Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose (PRADO)

Obesity

France, Canada, Brazil, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey, Bulgaria, Slovakia, Belgium, Czech Republic, Austria, Denmark, Egypt, Finland, Greece, Hungary, Ireland, Israel, Italy, Lithuania, Luxembourg, Mexico, Norway, United Kingdom
Sanofi

Completed

REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents (REASSURE)

Diabetes Mellitus, Type 2

Australia
University of Maryland, Baltimore
National Institute on Drug Abuse (NIDA)

Terminated

The Effects of Rimonabant, on Weight and Metabolic Risk Factors

Smoking | Hypertension | Obesity | Schizophrenia | Schizoaffective Disorder

United States
Sanofi

Terminated

Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors (RIALTO)

Obesity | Diabetes Mellitus, Type 2 | Dyslipidemia | Microalbuminuria

Spain
Hospital Nacional de Parapléjicos de Toledo

Completed

Effects of Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury (RIMOFATSCI-1)

Spinal Cord Injuries

Spain
Hospital Nacional de Parapléjicos de Toledo

Not yet recruiting

Effects of CB1 Antagonist/Reverse Agonist Rimonabant on Walking Abilities in Incomplete Spinal Cord Injury (RIMOFATSCI-2)

Spinal Cord Injuries

Spain
Sanofi

Withdrawn

Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Sanofi

Terminated

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes (ALLEGRO)

Diabetes Mellitus, Type 2

United States, Romania, Russian Federation, Spain, Sweden, India, Mexico, Denmark, Finland, Hungary, Italy, Korea, Republic of, Chile, Puerto Rico
Hospital Arnau de Vilanova
Pfizer

Unknown

Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases. (PRIMARIA)

Cardiovascular Diseases | Atherosclerosis

Spain

Search clinical trials for: Rimonabant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations